You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Novartis signs $1.3bn deal with UK-based Dunad

Novartis and Cambridge, UK-based Dunad Therapeutics have entered into a strategic collaboration – worth up to $1.3bn – to generate novel oral covalent and protein degrading small molecule drugs.